CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study.

Kim, DW; Kim, SW; Camidge, DR; Rizvi, NA; Marrone, KA; Le, XN; Blakely, C; Park, K; Chang, GC; Patel, SP; Cooper, ZA; Kumar, R; Samadani, R; McCombs, R; Pluta, M; Wu, KY; Ramalingam, S

CANCER RESEARCH, 2021; 81 (13):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索